Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells

235Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

Abstract

1. Hypercholesterolaemia often occurs in patients with type 2 diabetes, who therefore encounter administration of HMG-CoA reductase inhibitors. Alteration of pancreatic β-cell function leading to an impaired insulin secretory response to glucose plays a crucial role in the pathogenesis of type 2 diabetes. Therefore, it is important to examine the effects of HMG-CoA reductase inhibitors on β-cell function. 2. Cytosolic Ca2+ concentration ([Ca2+](i)) plays a central role in the regulation of β-cell function. The present study examined the effects of HMG-CoA reductase inhibitors on the glucose-induced [Ca2+](i) signalling and insulin secretion in rat islet β-cells. 3. Simvastatin, a lipophilic HMG-CoA reductase inhibitor, at 0.1-3 μg ml-1 concentration-dependently inhibited the first phase increase and oscillation of [Ca2+](i) induced by 8.3 mM glucose in single β-cells. The less lipophilic inhibitor, simvastatin-acid, inhibited the first phase [Ca2+](i) increase but was two orders of magnitude less potent. The hydrophilic inhibitor, pravastatin (100 μg ml-1), was without effect on [Ca2+](i). 4. Simvastatin (0.3 μg ml-1), more potently than simvastatin-acid (30 μg ml-1), inhibited glucose-induced insulin secretion from islets, whereas pravastatin (100 μg ml-1) had no effect. 5. Whole-cell patch clamp recordings demonstrated a reversible inhibition of the β-cell L-type Ca2+ channels by simvastatin, but not by pravastatin. Simvastatin also inhibited the [Ca2+](i) increases by L-arginine and KCl, agents that act via opening of L-type Ca2+ channels. 6. In conclusion, lipophilic HMG-CoA reductase inhibitors can inhibit glucose-induced [Ca2+](i) signalling and insulin secretion by blocking L-type Ca2+ channels in β-cells, and their inhibitory potencies parallel their lipophilicities. Precaution should be paid to these findings when HMG-CoA reductase inhibitors are used clinically, particularly in patients with type 2 diabetes.

Cite

CITATION STYLE

APA

Yada, T., Nakata, M., Shiraishi, T., & Kakei, M. (1999). Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. British Journal of Pharmacology, 126(5), 1205–1213. https://doi.org/10.1038/sj.bjp.0702397

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free